Get the Stockscreener App
36.97
3.52%
-1.35
Tg Therapeutics Inc stock is traded at $36.97, with a volume of 3.36M.
It is down -3.52% in the last 24 hours and down -14.00% over the past month.
See More
Previous Close:
$38.32
Open:
$37.97
24h Volume:
3.36M
Relative Volume:
1.31
Market Cap:
$6.03B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-336.09
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
-3.75%
1M Performance:
-14.00%
6M Performance:
+51.70%
1Y Performance:
+168.29%
1-Day Range:
$36.36
$40.19
1-Week Range:
$36.36
$40.19
52-Week Range:
$12.93
$43.32
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
36.97 | 6.03B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-24 | Initiated | TD Cowen | Buy |
| Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-26-23 | Resumed | Jefferies | Buy |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-01-20 | Initiated | JP Morgan | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Initiated | Evercore ISI | Outperform |
| Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
| Nov-14-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-17 | Initiated | Jefferies | Buy |
| Mar-06-17 | Reiterated | FBR & Co. | Outperform |
| Oct-06-16 | Resumed | Brean Capital | Buy |
| May-27-16 | Initiated | SunTrust | Buy |
| Dec-01-15 | Initiated | FBR Capital | Outperform |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| Aug-12-15 | Resumed | H.C. Wainwright | Buy |
| Jun-19-15 | Reiterated | Brean Capital | Buy |
| Dec-11-14 | Reiterated | ROTH Capital | Buy |
| Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
Where are the Opportunities in (TGTX) - news.stocktradersdaily.com
Exploring US High Growth Tech Stocks - simplywall.st
TG Therapeutics: Progress In MS Tempered By High Expectations (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by LPL Financial LLC - MarketBeat
TG Therapeutics Announces Data Presentations for BRIUMVI in Mult - GuruFocus
TG Therapeutics shares data on multiple sclerosis treatment By Investing.com - Investing.com South Africa
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why - MSN
TG Therapeutics Shares Rise Almost 30% In 3 Months: Here's Why - Barchart.com
TGTX: Promising Short Squeeze Opportunity with Biopharma Focus - GuruFocus
TG Therapeutics (TGTX) Highlights New Research on BRIUMVI® for M - GuruFocus
TG Therapeutics (TGTX) Struggles with Low ROE Despite High Debt - GuruFocus
TG Therapeutics shares data on multiple sclerosis treatment - Investing.com
TG Therapeutics Announces Data Presentations for BRIUMVI in - GlobeNewswire
Game-Changing MS Treatment? BRIUMVI Single-Dose Trial Reveals Breakthrough Potential - Stock Titan
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - The Manila Times
TG Therapeutics (TGTX) Shares Jump Amid Strong Briumvi Sales - GuruFocus
TG Therapeutics (TGTX) Highlights BRIUMVI® Data at Neurology Mee - GuruFocus
Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet? - simplywall.st
TG Therapeutics showcases BRIUMVI data at neurology meet - Investing.com
Game-Changing MS Treatment: BRIUMVI Reveals Exceptional Real-World Safety Profile - Stock Titan
TG Therapeutics reports on MS treatment switch By Investing.com - Investing.com South Africa
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals - GlobeNewswire
TG Therapeutics reports on MS treatment switch - Investing.com
Medical Journals Reveal Breakthrough: BRIUMVI Succeeds Where Other MS Treatments Fall Short - Stock Titan
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and TG Therapeutics (TGTX) - The Globe and Mail
(TGTX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
TGTX Gains as Roche's Ocrevus Fails in Phase 3 Trial; Impacting MS Market Dynamics - GuruFocus
TG Therapeutics rises after trial setback for high dose version of Roche’s MS drug - MSN
TG Therapeutics stock rises as Roche’s trial fails (TGTX) - Seeking Alpha
CRUCIAL INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm - ACCESS Newswire
Should We Be Cautious About TG Therapeutics, Inc.'s (NASDAQ:TGTX) ROE Of 11%? - Yahoo Finance
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? - MSN
Why TG Therapeutics Stock Was Soaring This Week - MSN
Based On Its ROE, Is TG Therapeutics, Inc. (NASDAQ:TGTX) A High Quality Stock? - simplywall.st
(TGTX) Investment Analysis and Advice - Stock Traders Daily
TG Therapeutics stock soars to 52-week high of $43.03 By Investing.com - Investing.com India
TG Therapeutics stock soars to 52-week high of $43.03 - Investing.com
TG Therapeutics (TGTX) technical analysisTG Therapeutics (NASDAQ:TGTX) - Benzinga
TG Therapeutics (TGTX): Among the Best Short Squeeze Stocks to Buy According to Analysts - Yahoo Finance
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies and Companies by DelveInsight - The Globe and Mail
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha
TG Therapeutics stock soars to 52-week high of $40.32 By Investing.com - Investing.com Australia
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials (NASDAQ:TGTX) - Seeking Alpha
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):